▴ Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity.
▴ Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in obese, but otherwise healthy, patients during ≤2 years' orlistat treatment; serum triglyceride and high density and very low density lipoprotein-cholesterol levels were unchanged in trials of ≤12 weeks.
▴ Obese patients who were maintained on a hypocaloric diet and who received orlistat 360 mg/day for 12 weeks lost a significantly greater percentage of bodyweight than placebo recipients (5 vs 3.5%).
▴ In 2-year studies, weight loss was significantly greater in orlistat than in placebo recipients by the end of year 1; weight was further reduced or maintained in the second year, when a eucaloric diet was allowed, in orlistat but not placebo recipients.
▴ A greater proportion of orlistat than placebo recipients lost >5% or >10% of their initial bodyweight in 1- and 2-year studies.
KeywordsAdis International Limited Placebo Recipient Orlistat Lipase Inhibitor Orlistat Treatment
Unable to display preview. Download preview PDF.
- 1.Obesity: advances in understanding and treatment. Drug Mark Dev 1995 May 22; 6: 26–41Google Scholar
- 4.Pisunyer. Guidelines for the approval and use of drugs to treat obesity — a position paper of the North American Association for the Study of Obesity. Obes Res 1995 Sep; 3: 473–8Google Scholar
- 5.Atkinson RL, Blank RC, Loper JF, et al. Combined drug treatment of obesity. Obes Res 1995 Nov; 3 Suppl. 4: 497–500Google Scholar
- 7.Weibel EK, Hadvary P, Hochuli E, et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity [in English]. J Antibiot Tokyo 1987 Aug; 40: 1081–5Google Scholar
- 10.Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor ro-18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992 Jan; 55 Suppl.: 309–13Google Scholar
- 15.Drent ML, Larsson I, Williamolsson T, et al. Orlistat (RO 180647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995 Apr; 19: 221–6Google Scholar
- 16.Lucas C. A 2-year placebo-controlled study of orlistat in the treatment of obesity [abstract no. 0339]. Diabetes 1997 May; 46 Suppl. 1: 86AGoogle Scholar
- 18.Noack R. Two-year study of orlistat in the treatment of obesity [abstract]. 79th Annual meeting of the American Endocrine Society (June 1997)Google Scholar
- 30.Canovatchel W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor [abstract]. F. Hoffmann-La Roche (New Jersey). 1997 (Data on file). Presented at the 16th IDF Congress, Helsinki, 1997Google Scholar
- 32.Hollander P. A 57-week study of orlistat in the treatment of obese patients with NIDDM [abstract no. 0213]. Diabetes 1997 May; 46 Suppl. 1: 55AGoogle Scholar
- 33.Roche 1998. Xenical® (orlistat) Advisory Committee briefing document. Presented at the Advisory Committee. 1998 Mar 13Google Scholar